Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Study Overview
=================
Brief Summary
-----------------
Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Detailed Description
-----------------
Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness. The strongest fucoidan among all seaweed for inhibiting cancer cells is in Okinawa Japanese waters. For chemically speaking, the major components for fucoidan consisted of mainly fucose which is a kind of polysaccharide with strong biological activity. However, patients need to take actual fucoidan in order to reach the best effectiveness for inhibiting cancer cell. Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Official Title
-----------------
Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Conditions
-----------------
Non-alcoholic Fatty Liver Disease

Intervention / Treatment
-----------------
* Other: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
* Other: placebo pills


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are aged between 20-75 with non alcoholic fatty liver disease (NAFLD). Exclusion Criteria: Patients were allergic to seafood. Patients who take Vitamin E or Pioglitazone.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fucoidan use<br>FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper) | Other: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin<br>* Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.<br>|
| Placebo Comparator: placebo pills<br>placebo capsule 6 per day (before breakfast and supper) | Other: placebo pills<br>* taking placebo pills as if patients are under treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in ALT Index | Measure the first month and the sixth-month change in the index which is ALT related to Liver inflammation. | 6 months | 
| Change in AST Index | Measure the first month and the sixth-month change in the index which is AST relate to Liver inflammation | 6 months | 
| Change in HbA1c | Measure the first month and the sixth-month change in the index which is HbA1c relate to Liver inflammation | 6 months |